Ibogaine's pharmacokinetics — the way the body absorbs, distributes, metabolizes, and eliminates it — are unusually complex compared to most psychoactive compounds. A slow onset, long half-life, conversion to an active metabolite, and accumulation in fatty tissue all contribute to a multi-day experience with safety implications that researchers and clinicians continue to study carefully.

How Is Ibogaine Absorbed Into the Body?

In clinical and research settings, ibogaine is administered orally, typically as ibogaine hydrochloride or a total alkaloid extract from Tabernanthe iboga root bark. After ingestion, it is absorbed through the gastrointestinal tract. Peak plasma concentrations generally appear within 1 to 4 hours of ingestion, though the onset of subjective effects — often described as a visionary or oneirogenic state — can lag behind measurable blood levels by 45 minutes or more.

Food, gastric motility, and individual variation in gut absorption enzymes can influence the rate and extent of uptake. Bioavailability data from human studies remain limited, partly because conducting controlled pharmacokinetic trials in a Schedule I context requires specific DEA and IRB approvals. Animal studies and the handful of existing human pharmacokinetic investigations suggest oral bioavailability is moderate, with significant first-pass hepatic metabolism occurring before ibogaine reaches systemic circulation.

How Does Ibogaine Distribute Through the Body?

Once in systemic circulation, ibogaine is highly lipophilic — it dissolves readily in fat — and distributes widely into tissues, including the brain, liver, and adipose (fat) tissue. This high lipophilicity produces a large volume of distribution, meaning most of the drug is outside the bloodstream at any given time, sequestered in tissues rather than plasma.

This tissue sequestration has a critical practical consequence: ibogaine and its primary metabolite, noribogaine, can be released back into circulation slowly over hours and days. Researchers at the University of Miami and elsewhere have noted that this redistribution contributes to the prolonged duration of ibogaine's effects and may explain why cardiac monitoring is recommended well beyond the initial dosing window.

Safety Note: Ibogaine's wide tissue distribution and slow redistribution mean cardiac risks — specifically QT interval prolongation, which can precipitate life-threatening arrhythmias — can persist 24 hours or longer after the initial dose. Published case reports and pharmacological analyses (Koenig & Hilber, 2015) document fatalities associated with cardiac events during and after ibogaine administration. Medical screening and continuous cardiac monitoring are considered essential by researchers working in legal jurisdictions.

What Is Noribogaine and Why Does It Matter?

The liver converts ibogaine primarily into noribogaine (also called 12-hydroxyibogamine) via O-demethylation, a reaction mediated largely by the cytochrome P450 enzyme CYP2D6. Noribogaine is not merely a waste product — it is pharmacologically active in its own right, and in many respects its profile differs meaningfully from the parent compound.

  • Longer half-life: Noribogaine's elimination half-life ranges from roughly 24 to 49 hours in human studies (Glue et al., 2015), compared to ibogaine's half-life of approximately 4 to 7 hours. This means noribogaine can remain at measurable plasma concentrations for several days after a single dose of ibogaine.
  • Distinct receptor profile: Noribogaine has higher affinity for the serotonin transporter (SERT) than ibogaine does, and shows strong activity at kappa-opioid receptors — a profile linked to mood modulation and potentially to the anti-addictive effects observed in opioid-dependent patients.
  • Lower psychedelic intensity: The visionary, dissociative phase of ibogaine experience is thought to correlate more closely with ibogaine itself; noribogaine's longer presence may contribute to the calmer, reflective "after-glow" period patients often describe in the days following treatment.

Because CYP2D6 activity varies significantly between individuals — with poor metabolizers producing noribogaine more slowly and extensive metabolizers converting ibogaine faster — pharmacokinetics are not uniform across patients. This genetic variability is one reason standardized dosing protocols remain an active area of research.

How Long Does Ibogaine Stay in the System?

Ibogaine itself clears relatively quickly from plasma, with a half-life of 4–7 hours in most studies. However, because of deep tissue binding and the long-lived noribogaine metabolite, the functional presence of ibogaine-related compounds in the body is considerably longer:

  • Noribogaine reaches peak plasma levels 1–2 hours after ibogaine peaks and remains detectable for 2 to 4 days in most individuals.
  • In urine toxicology, noribogaine may be detectable for up to 4 weeks depending on dose, body composition, and individual metabolism.
  • A second, minor metabolite — ibogaine noribogaine glucuronide — undergoes renal excretion and extends the analytical detection window further.

This prolonged pharmacological presence distinguishes ibogaine from shorter-acting psychedelics and has direct implications for monitoring windows in clinical trial protocols.

Which Enzymes and Receptors Are Most Important?

Ibogaine interacts with a broad range of molecular targets, which partly explains why characterizing its pharmacokinetics requires understanding both metabolic enzymes and pharmacodynamic receptor binding:

  • CYP2D6: Primary enzyme responsible for converting ibogaine to noribogaine. Also inhibited by ibogaine itself, meaning ibogaine can slow its own metabolism — a phenomenon called mechanism-based inhibition.
  • CYP3A4: Secondary metabolic pathway; relevant when CYP2D6 activity is low or saturated.
  • hERG potassium channels: Ibogaine and noribogaine both block cardiac hERG channels, prolonging the QT interval and creating arrhythmia risk. This is the dominant pharmacokinetic-pharmacodynamic safety concern.
  • NMDA receptors, sigma-2 receptors, and opioid receptors: Contribute to ibogaine's anti-addictive, analgesic, and psychoactive properties but are secondary to safety calculations around clearance timing.

How Do Pharmacokinetics Influence Treatment Protocols?

In jurisdictions where ibogaine treatment is legal — including Mexico, Brazil, Canada, New Zealand, and several European countries — treatment centers typically structure their protocols around these pharmacokinetic realities. A single therapeutic dose (commonly 10–20 mg/kg of ibogaine hydrochloride in research settings) produces an acute psychoactive phase lasting roughly 4–8 hours, followed by a residual stimulant/reflective phase of 8–20 hours, with noribogaine pharmacodynamic activity persisting for days thereafter.

Published observational data (Mash et al., 2000; Noller et al., 2018) support continuous cardiac telemetry for at least 24 hours post-dosing, electrolyte optimization before administration, and careful screening for pre-existing QT prolongation, cardiac disease, and CYP2D6 inhibiting co-medications. The Stanford ibogaine study (2023, published in Nature Medicine) incorporated these pharmacokinetic principles into protocol design for a veteran population, reporting significant reductions in PTSD, depression, and alcohol use at one-month follow-up.

Legal Status Note: Ibogaine is a Schedule I controlled substance in the United States, making personal possession, distribution, and unsupervised use illegal under federal law. Pharmacokinetic research in the US requires Schedule I researcher registration from the DEA. Clinical use is currently available only in countries where ibogaine is legal or unscheduled.

Frequently Asked Questions

The acute visionary phase correlates with ibogaine's plasma peak and typically lasts 4–8 hours. A subsequent stimulant and introspective phase can persist 8–20 hours. Because noribogaine has a half-life of 24–49 hours, pharmacologically active compounds remain in the body for 2–4 days after dosing, influencing mood, sleep, and cardiac function throughout that window.
CYP2D6 is the primary enzyme that converts ibogaine to noribogaine. People classified as poor metabolizers (roughly 5–10% of European-ancestry populations) convert ibogaine more slowly, leading to higher and more prolonged ibogaine plasma levels and potentially greater cardiac risk. Extensive or ultra-rapid metabolizers may convert ibogaine quickly, altering the ratio of parent compound to metabolite. Some researchers advocate CYP2D6 genotyping before treatment.
Noribogaine has stronger affinity for the serotonin transporter (SERT) and kappa-opioid receptors than ibogaine does, and is less potent at NMDA receptors. It is considered less intensely psychoactive but may contribute substantially to the anti-craving and mood-stabilizing effects observed after ibogaine treatment. Its longer half-life means its influence outlasts ibogaine's by days. Researchers at Victoria University of Wellington studied noribogaine as a standalone compound in Phase I trials (Glue et al., 2015).
Because ibogaine accumulates in fat and other tissues, redistribution back into plasma can occur hours after peak dosing. This means cardiac effects — particularly QT prolongation — may not track linearly with the subjective experience. Someone who appears to be through the acute phase may still have pharmacologically significant plasma concentrations. This is why published protocols recommend extended cardiac monitoring well beyond the point when the patient feels recovered.
Yes. Ibogaine inhibits CYP2D6, meaning drugs that rely on CYP2D6 for metabolism — including many antidepressants, antipsychotics, and opioids — may accumulate to higher-than-expected levels when taken alongside ibogaine. Additionally, any medication that independently prolongs the QT interval (a long list including methadone, certain antifungals, and antiemetics) compounds cardiac risk. Comprehensive medication review before ibogaine administration is standard practice in responsible clinical settings.
Ibogaine is primarily eliminated via hepatic metabolism to noribogaine, which is subsequently glucuronidated and excreted renally. A smaller fraction is excreted unchanged in feces via biliary routes. Because elimination depends heavily on liver function and CYP enzyme activity, individuals with hepatic impairment may experience significantly prolonged exposure. Renal excretion of conjugated metabolites means kidney function also influences overall clearance timelines.
Human pharmacokinetic data remain limited but are growing. The New Zealand noribogaine Phase I/II trials (Glue et al.) generated some of the most rigorous human PK data available. The VETS (Veterans Exploring Treatment Solutions) study at Stanford, published in Nature Medicine in 2023, included pharmacokinetic monitoring. Additional trials are being designed under FDA guidance as researchers pursue Breakthrough Therapy or IND pathways, which will produce more standardized human PK datasets in coming years.

Understanding ibogaine's pharmacokinetics is foundational to evaluating both its therapeutic potential and its risk profile. Anyone researching ibogaine treatment — whether for addiction, PTSD, or depression — should consult with a physician experienced in psychedelic medicine, ensure access to cardiac monitoring, undergo thorough medication and medical history review, and work only with programs operating in jurisdictions where ibogaine is legal. Pharmacogenomic testing for CYP2D6 status may also be worth discussing with a clinician before any treatment decision.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.